Topiramate in Migraine Prevention: A 2016 Perspective.

@article{Silberstein2017TopiramateIM,
  title={Topiramate in Migraine Prevention: A 2016 Perspective.},
  author={Stephen David Silberstein},
  journal={Headache},
  year={2017},
  volume={57 1},
  pages={
          165-178
        }
}
BACKGROUND In evidence-based guidelines published in 2000, topiramate was a third-tier migraine preventive with no scientific evidence of efficacy; recommendation for its use reflected consensus opinion and clinical experience. Its neurostabilizing activity, coupled with its favorable weight profile, made topiramate an attractive alternative to other migraine preventives that caused weight gain. When guidelines for migraine prevention in episodic migraine were published in 2012, topiramate was… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 134 REFERENCES

Canadian Headache Society guideline for migraine prophylaxis.

  • The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • 2012
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Retrospective claimsbased comparative health outcomes study : Trokendi XR V R ( extended - release topiramate ) vs . immediaterelease topiramate

W O’Neal, E Hur, T Liranso, R Turner
  • 2016